Running to Stand Still? How Mild Exercise May Protect Your Brain
"Discover how moderate running could be a key to slowing down neurodegeneration, keeping your brain healthy as you age."
As we age, our bodies and minds undergo changes, and the risk of neurodegenerative diseases like Parkinson's increases. However, emerging research suggests that lifestyle interventions, such as regular physical exercise, can play a crucial role in maintaining brain health and slowing down the progression of these diseases.
Parkinson's disease (PD) is a debilitating condition characterized by the loss of dopaminergic neurons in the substantia nigra, a brain region responsible for motor control. This loss leads to motor and non-motor symptoms that significantly impair quality of life. While aging is a primary risk factor, genetic and environmental factors also contribute to the development of PD.
A new study published in the Journal of Sports Sciences explores the potential of mild running to protect the substantia nigra during the early stages of neurodegeneration. This research provides compelling evidence that moderate exercise can have significant benefits at the cellular level, potentially delaying the onset and progression of Parkinson's disease.
Parkinson’s Growing Global Burden
Parkinson’s disease (PD) is a common neurodegenerative disorder that can severely affect quality of life. A 2026 epidemiological study updated estimates of PD prevalence, incidence, mortality, and disability-adjusted life years from 1990 to 2021 across global, regional, national, age, gender, and Socio-demographic Index categories. In the United States, nearly 90,000 people are diagnosed each year, while the Parkinson’s Foundation estimates combined direct and indirect costs at nearly $25 billion annually.
Symptom Control Without Disease Modification
PD is classically identified by motor manifestations including bradykinesia, resting tremor, rigidity, and postural instability, although it also includes non-motor symptoms. Current therapies are largely symptomatic, using dopaminergic medicines or neurosurgical interventions to restore dopamine signaling and relieve motor symptoms. These approaches do not modify the disease course or prevent neurodegeneration, and long-term treatment can involve adverse effects and motor fluctuations.
Two Centuries of Parkinson’s Research
The written history of Parkinson’s disease begins in 1817, when British physician James Parkinson published An Essay on the Shaking Palsy. The disease was later understood through discoveries about its clinical and pathological characteristics, anatomy, and related mechanisms. A 2017 review described these developments as milestones spanning 200 years of PD research.
How Does Moderate Running Protect the Brain?
The study, conducted on aged male Lewis rats, investigated the effects of moderate treadmill running on the substantia nigra during early neurodegeneration induced by rotenone, a pesticide known to cause Parkinson's-like symptoms. The rats were divided into groups that were either sedentary or engaged in moderate treadmill running for six weeks, starting four weeks after rotenone exposure.
- Alpha-Synuclein Levels: Rotenone exposure typically increases alpha-synuclein, a protein that aggregates in Parkinson's disease. However, the running regimen prevented this increase.
- Tyrosine Hydroxylase (TH) Levels: TH is an enzyme crucial for dopamine production. Running helped maintain TH levels, which are often reduced in Parkinson's.
- Autophagy and Mitophagy: Exercise stimulated autophagy (the process of clearing out damaged cells) and mitophagy (the removal of damaged mitochondria). This is crucial because mitochondrial dysfunction is a hallmark of Parkinson's.
- Oxidative Stress: Running helped prevent the increase in hydrogen peroxide (H2O2), a marker of oxidative stress that can damage brain cells.
- Proteasome Activity: While exercise alone decreased proteasome activity (protein degradation), it showed some protective effects in the rotenone-exposed group.
An Evolving Research Picture
Recent reviews continue to examine Parkinson’s disease as a progressive neurodegenerative condition involving both motor and non-motor symptoms. Research in this area is still developing, so emerging findings should be interpreted as evidence that may refine current understanding rather than as definitive clinical guidance. The available material supports continued investigation into how PD begins, progresses, and might eventually be treated beyond symptom relief.
Why Current Treatment Is Not Enough
Although modern Parkinson’s treatments can provide meaningful relief, current long-term treatment standards still have important limitations. The disease-modification conundrum remains that advances in pathology and pharmacology have produced effective clinical therapies without establishing a reliable way to halt neurodegeneration. Recent discussions therefore emphasize multidisciplinary care and acknowledge persistent challenges in diagnosis, research, treatment, and healthcare delivery.
PD Within the Parkinsonian Syndromes
Parkinson’s disease is associated with ongoing degeneration of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies containing α-synuclein. It shares clinical, neuropathological, and genetic features with dementia with Lewy bodies, progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy. These conditions are grouped as parkinsonian syndromes, but their overlapping features do not make them identical diseases.
What This Means for You
The study provides compelling evidence that incorporating moderate physical activity like running into your routine can have a significant impact on your brain health, particularly as you age. While further research is needed to fully understand the underlying mechanisms and translate these findings to humans, the results suggest that regular exercise can be a powerful tool in preventing or delaying the onset of neurodegenerative diseases.
Multiple Pathways Shape Progression
Parkinson’s disease is pathologically defined by the death of dopaminergic neurons in the pars compacta of the substantia nigra. The cause of this multifaceted disease remains largely unclear, which may help explain why disease-modifying therapies are still lacking. Neuroinflammation, mitochondrial dysfunction, and impaired proteostasis are among the mechanisms receiving attention as possible contributors to neurodegeneration.
From Symptom Relief to Disease Modification
Future Parkinson’s research is focused on understanding disease mechanisms and developing treatments that do more than relieve symptoms. Current dopaminergic medications and deep brain stimulation can improve symptoms but do not halt progression. Reviews identify molecular research and disease-modifying strategies as important priorities for advancing PD care.
Beyond a Single Treatment
Parkinson’s disease creates challenges that extend beyond the neurological symptoms themselves. Its progressive nature can affect movement, daily function, and quality of life, while effective care may require more than one type of intervention. This broader context suggests that research and healthcare planning must consider long-term support as well as biological treatment.
Evidence From Everyday Life
Real-world data are being studied to identify marketed drugs that might have disease-modifying effects on Parkinson’s disease progression. A pilot analysis reported that mobility measured through actigraphy can predict PD disease severity and may help screen for early declines in physical function-related quality of life. A separate case report described the trajectory of a 75-year-old retired occupational female therapist with idiopathic PD diagnosed at Hoehn and Yahr stage 2, illustrating how individual experiences can complement population-level evidence.